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Background and Objectives: A variety of demographic factors,
sex, and degree of immunosuppression can influence anti-
retroviral drug concentrations. The authors studied the influ-
ence of immune status, sex, and body mass index (BMI) on
the steady-state pharmacokinetics of nevirapine delivered as
a fixed-dose combination in HIV-1-infected patients in India.
Methods: Twenty-six HIV-1-infected adult patients undergoing
treatment with nevirapine-based highly active antiretroviral
therapy regimens participated in the study. Pharmacokinetic
variables were compared between patients divided based
on CD4 cell counts, sex, and BMI. Results: Patients with
higher BMI had lower peak and trough concentration and
exposure of nevirapine than those with lower BMI; none of
the differences in the pharmacokinetic variables of nevi-
rapine between the various patient groups was statistically
significant. Conclusions: Patients’ immune status, sex, or BMI
had no impact on the pharmacokinetics of nevirapine. Plasma
nevirapine concentrations were maintained within the ther-
apeutic range of the drug in the majority of the patients.
Keywords: pharmacokinetics; nevirapine; India; immune status;
sex; BMI
Access to antiretroviral drugs for HIV-1-infected patients
in developing countries is a global public health pri-
ority. The World Health Organization currently rec-
ommends first-line therapy with 2 nucleoside reverse
transcriptase inhibitors (NRTIs) and 1 non-NRTI
(NNRTI)⎯a combination with good efficacy, tolerabil-
ity, simplicity, and low cost.1 Generic fixed-dose com-
binations (FDCs) of such regimens are widely regarded
as crucial for scaling up AIDS treatment in developing
countries. Two triple-drug combinations consisting of
nevirapine and lamivudine with either stavudine or
zidovudine as the third agent are available as FDCs in
the developing world. A vast majority of HIV-infected
patients in India receive nevirapine-based highly
active antiretroviral therapy (HAART), the common
co-drugs being lamivudine and stavudine.2 A few
studies have reported the effectiveness and safety of
generic FDCs for treatment of HIV-1-infected adults.2-5
It has been suggested that a variety of demographic
factors such as age, body size, and weight can influ-
ence antiretroviral drug concentrations.6 Sex-based
differences in the pharmacokinetics of nevirapine
have also been observed.7 Keating et al reported that
malabsorption correlates significantly with the degree
of immunosuppression.8 We undertook a study to
obtain information on the pharmacokinetics of nevi-
rapine in HIV-infected patients on treatment with
FDCs in India, as well as the influence of immuno-
logical status, sex, and body mass index (BMI) on the
pharmacokinetics of these drugs, as very limited
information is available on this aspect.
Methods
Patients
The study participants were composed of HIV-infected
patients of ethnic Indian origin who were participating
in a controlled clinical trial and were being followed
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up at regular intervals. During each follow-up visit,
they underwent a complete medical examination and
were tested for biochemical and hematological para-
meters and CD4 cell counts. The patients were required
to meet the following inclusion criteria: (1) 18 to 50
years of age, (2) body weight not less than 30 kg, (3) no
severe hepatic or renal dysfunction (serum transami-
nases within 2 1/2 times the upper limit of normal
range and creatinine < 1.2 mg/dl), (4) nondiabetic
(random blood glucose between 80 and 140 mg/dl),
(5) undergoing treatment with generic FDC of
antiretroviral drugs (nevirapine 200 mg/lamivudine
150 mg/stavudine 30/40 mg bi-daily) for a minimum
period of 2 weeks, (6) not suffering from any serious
opportunistic infection that could cause malabsorp-
tion of drugs, and (7) willingness to participate in the
study and provide informed written consent. Chronic
alcoholics and female patients on hormonal birth
control pills were excluded from the study.
Conduct of Study
The study was conducted at the Government
Hospital of Thoracic Medicine, Tambaram, Chennai,
India. Eligible study participants were admitted to
the hospital at least a day prior to start of the study.
On the day of the study, blood samples (3 ml) were
drawn in heparinized containers before dosing (0 hour)
and serially at 0.5, 1, 2, 4, 6, 8, and 12 hours after
administration of the FDC pill (Cipla/Ranbaxy/Alkem/
Emcure) with 200 ml water. The blood samples were
centrifuged immediately and plasma was stored at
−20ºC until estimation of nevirapine was undertaken.
The study was conducted after obtaining clearance
from the Institutional Ethics Committee. Informed
written consent was obtained from all the patients.
Estimation of Plasma Nevirapine
Estimation of plasma nevirapine was carried out by
HPLC (Shimadzu Corporation, Kyoto, Japan) accord-
ing to validated methods described earlier.9
Pharmacokinetic Analysis
Maximum concentration (Cmax), minimum concen-
tration (Cmin), and time to attain Cmax (Tmax) were
determined by visual inspection of data. Drug con-
centration-time data were analyzed by noncompart-
mental model following first-order kinetics using
WinNonlin software (Version 4.1) (Pharsight Corpo-
ration, Mountain View, CA). The linear trapezoidal
rule was used to compute the exposure (AUC0-12).
Elimination half-life (t ½) was obtained by dividing
0.693 with elimination rate constant (Kel).
Statistical Evaluation
Analysis of data was performed using SPSS (version
10) package. The significance of differences in the
pharmacokinetic parameters of nevirapine between
various groups of patients was calculated using non-
parametric Mann-Whitney test. A P value of ≤ .05 was
considered to be statistically significant. Pearson’s
correlation test was used to evaluate the correlation
between Cmax and AUC0-12 of nevirapine with that of
patients’ body weight. Repeated measures analysis
was used to study the trend of plasma nevirapine
levels over time (0 to 12 hours) versus BMI.
Results
The baseline characteristics of study participants are
provided in Table 1. The mean CD4 cell counts at
baseline, 6 months, and 12 months were 99, 320, and
414 cells/mm3, respectively. Comparison of pharma-
cokinetic variables of nevirapine in patient groups
divided based on CD4 cell counts (< and ≥ 200 cells/
mm3), sex (males and females), and BMI (< 18.5 and
≥ 18.5) were made. The normal range of BMI was
taken as 18.5 to 24.9.10 It was observed that patients with
a BMI ≥ 18.5 had lower Cmax (7.48 vs 8.95 µg/ml), Cmin
(4.70 vs 5.81 µg/ml), and AUC0-12 (69.31 vs 85.74 µg/
ml) than those with a BMI < 18.5; however, these dif-
ferences were not statistically significant (Table 2).
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Table 1. Baseline Characteristics of Study Participants
Characteristic Value
Gender (No.)
Males 16
Females 10
Age (years)
Mean 36
Range 26-50
Body weight (kg)
Mean 53
Range 35-91
Height (cm)
Mean 159
Range 140-173
BMI
Mean 20.8
Range 15.1-33.0
Duration of ART (months)
Mean 4.6
Range 1-17
CD4 counts (cells/mm3)
Mean 230
Range 25-684
≥ 200 cells/mm3 (No.) 13
< 200 cells/mm3 (No.) 13
BMI = body mass index; ART = antiretroviral therapy.
Repeated measures analysis showed that there was a
significant trend in plasma nevirapine over time in
patients with a BMI < and ≥ 18.5 (P < .05) (Figure 1).
But the difference in plasma nevirapine between the
2 groups of patients was not significant. None of the
differences in the pharmacokinetic variables of nevi-
rapine between the various patient groups was statisti-
cally significant. We did not observe a significant
correlation between patients’ body weight and Cmax
and AUC0-12 of nevirapine.
Discussion
Antiretroviral drug concentrations are among the
most important determinants of clinical response to
a drug accounting for both toxicity and efficacy. This
study presents the pharmacokinetic profile of nevi-
rapine taken as a generic FDC in HIV-infected patients
in India. All the patients were obtaining antiretroviral
drugs from the government antiretroviral therapy
(ART) clinic. The majority of the patients had ade-
quate nevirapine concentrations, which were within
the therapeutic range of the drug (3-12 µg/ml). Four
patients had nevirapine peak concentrations above
the upper limit of the therapeutic range of 12 µg/ml.
Three of the 4 patients had a BMI of > 21, whereas in
1 patient the BMI was 17.5. None had any obvious
symptoms related to drug toxicity. However, hepato-
toxicity was not monitored prospectively in these
patients and transient liver enzyme abnormalities could
have been missed. A similar observation has been
made by Kappelhoff et al,11 who did not observe any
relationship between nevirapine exposure and devel-
opment of adverse events. Three patients who had
their nevirapine trough concentrations below 3 µg/ml
showed a significant increase in their CD4 cell counts.
Several studies have found that sex can have a
modest influence on the pharmacokinetic profile of
some antiretroviral drugs. Exposure of nevirapine
has been reported to be 20% higher in females than
in males.7 However, our study did not observe any sig-
nificant difference in the pharmacokinetics of nevi-
rapine between males and females. Keating et al
observed that malabsorption and increased intestinal
permeability are common in AIDS patients and that
malabsorption correlated significantly with the
degree of immune suppression and BMI.8 The study
findings demonstrate that adequate nevirapine levels
are maintained in blood irrespective of the stage of
immune suppression and BMI.
Peak and trough concentrations and exposure of
nevirapine observed in the present study are markedly
higher in the Indian population of HIV-infected
patients than those reported in the American and
European populations.12-17 This could be due to the
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Table 2. Steady-State Pharmacokinetics of Nevirapine
Mean ± SD
Variable N Cmax (µg/ml) Cmin (µg/ml) Tmax (h) AUC0-12 (µg/ml.h) t ½ (h)
Sex
Males 16 8.38 ± 2.45 5.47 ± 2.06 1.53 ± 0.97 79.67 ± 27.68 33.74 ± 26.46
Females 10 8.70 ± 2.55 5.46 ± 2.10 1.15 ± 0.47 82.38 ± 26.87 23.55 ± 18.07
BMI
< 18.5 18 8.95 ± 2.43 5.81 ± 2.04 1.42 ± 0.86 85.74 ± 27.31 29.57 ± 22.44
≥ 18.5 8 7.48 ± 2.29 4.70 ± 1.92 1.31 ± 0.80 69.31 ± 23.47 30.40 ± 21.24
CD4 cell counts
(cells/cu.mm)
< 200 13 8.66 ± 2.44 5.48 ± 2.17 1.62 ± 0.94 82.25 ± 29.46 28.74 ± 15.41
≥ 200 13 8.34 ± 2.53 5.45 ± 1.98 1.15 ± 0.66 79.13 ± 25.09 34.90 ± 16.11
Overall 26 8.50 ± 2.44 5.05 ± 2.04 1.38 ± 0.83 80.69 ± 26.85 29.82 ± 11.66
Cmax = peak concentration; Cmin = trough concentration; Tmax = Time to attain Cmax; AUC = area under the plasma concentration versus
time curve; t ½ = half-life; BMI = body mass index.
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Figure 1 Mean plasma nevirapine (NVP) over time (0 to 12 hours)
versus body mass index (BMI). Trend analysis of plasma NVP
versus BMI in 26 HIV-infected patients.
fact that Indian patients weigh less than Europeans and
Americans and that nevirapine clearance is dependent
on body weight.18 However, the present study data are
very similar to that observed in Malawians, who had a
mean peak concentration of 9.3 µg/ml.14 It would
therefore be interesting to explore pharmacogenetic
differences that could impact drug levels in different
populations.
The effectiveness of nevirapine-based HAART
delivered as a generic FDC has been reported.2-5 A
limitation of this study is that although all the
patients were receiving treatment at the same ART
center, they could have received drugs from different
companies, which we were not able to control. Our
study has clinical implications for treatment of HIV-
infected patients in resource-constrained settings.
Earlier, we had shown that malabsorption of antitu-
berculosis drugs occurs in patients with advanced
HIV disease with and without diarrhea.19 Adequate
plasma concentrations of nevirapine that are not
influenced by the stage of immune suppression, sex,
and BMI observed in this study are encouraging.
Hence, if patients take regular treatment, chances of
failure due to inadequate drug levels are low. A regu-
lar follow-up of these patients has shown a steady
increase in their CD4 cell counts following treatment.
Although a majority of the patients started antiretro-
viral therapy at advanced stages of HIV infection,
there was still remarkable improvement in CD4
counts, indicating the potency of generic FDC regi-
mens. Finally, this study provides one more piece of
evidence that generic fixed drug combinations man-
ufactured and widely used in the developing world
(in this case, through the Indian government-run
antiretroviral treatment program) are effective and,
if used regularly, can improve the health status of mil-
lions of patients who require antiretroviral therapy.
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